Literature DB >> 7868254

Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: comparison with activities of synthetic material of the proposed structure and analogs.

J R Rose1, W J Christ, J R Bristol, T Kawata, D P Rossignol.   

Abstract

Lipid A from the photosynthetic bacterium Rhodobacter sphaeroides (RSLA) has been previously shown to antagonize many of the effects of endotoxins from more pathogenic gram-negative bacteria. We have reported on the synthesis of the proposed structure of RSLA and determined that bacterially derived RSLA is not identical to its proposed structure (W.J. Christ, P. D. McGuinness, O. Asano, Y. Wang, M. A. Mullarkey, M. Perez, L. D. Hawkins, T. A. Blythe, G. R. Dubuc, and A. L. Robidoux, J. Am. Chem. Soc. 116:3637-3638, 1994). Here we report results of analyzing the antagonistic and agonistic activities of bacterially derived RSLA in comparison with the activities of chemically synthesized material of the proposed structure of RSLA and analogs. Results indicated that all compounds were approximately equally potent at inhibiting endotoxin-induced release of tumor necrosis factor alpha from human monocytes and human whole blood as well as endotoxin-induced generation of nitric oxide in murine macrophages. In addition, all compounds were of equivalent potencies at inhibiting the binding of 125I-labelled lipopolysaccharide derivatized with 2-(p-azido-salicylamido) ethyl-1-3'-dithiopropionate to murine macrophages. Higher concentrations of bacterially derived RSLA (10 to 100 microM) were agonistic in human and murine assays. In gamma interferon-treated murine macrophages, agonism was exhibited at concentrations as low as 100 nM. In contrast, all synthetic materials were either dramatically less agonistic or devoid of agonistic activity when tested at concentrations as high as 100 microM. It is possible either that bacterially derived RSLA contains a small amount of a highly agonistic impurity or that the agonistic activity of RSLA is intrinsic to its molecular structure. In either case, these biological results support our previous report concluding that biologically derived RSLA is not identical to synthetic material of its proposed structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7868254      PMCID: PMC173078          DOI: 10.1128/iai.63.3.833-839.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis by Rhodobacter sphaeroides diphosphoryl lipid A is dependent on corticosterone induction.

Authors:  S H Zuckerman; N Qureshi
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

2.  Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway.

Authors:  R L Kitchens; R J Ulevitch; R S Munford
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

Review 3.  Lipopolysaccharide antagonists.

Authors:  W A Lynn; D T Golenbock
Journal:  Immunol Today       Date:  1992-07

4.  Lipopolysaccharide (LPS) binding to 73-kDa and 38-kDa surface proteins on lymphoreticular cells: preferential inhibition of LPS binding to the former by Rhodopseudomonas sphaeroides lipid A.

Authors:  M G Lei; N Qureshi; D C Morrison
Journal:  Immunol Lett       Date:  1993-06       Impact factor: 3.685

5.  Modulation of lipopolysaccharide-induced macrophage gene expression by Rhodobacter sphaeroides lipid A and SDZ 880.431.

Authors:  C L Manthey; P Y Perera; N Qureshi; P L Stütz; T A Hamilton; S N Vogel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

6.  Regulation of cytokine mRNA expression in lipopolysaccharide-stimulated human macrophages.

Authors:  W W Zhong; P A Burke; A T Hand; M J Walsh; L A Hughes; R A Forse
Journal:  Arch Surg       Date:  1993-02

7.  Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA.

Authors:  S H Zuckerman; G F Evans; L Guthrie
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

8.  Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes.

Authors:  D T Golenbock; R Y Hampton; N Qureshi; K Takayama; C R Raetz
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

9.  Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice.

Authors:  S J Green; C A Nacy; R D Schreiber; D L Granger; R M Crawford; M S Meltzer; A H Fortier
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide.

Authors:  R B Lorsbach; W J Murphy; C J Lowenstein; S H Snyder; S W Russell
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

View more
  14 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro.

Authors:  N G Barclay; J C Spurrell; T F Bruno; D G Storey; D E Woods; C H Mody
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 4.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

5.  Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS.

Authors:  B W Jarvis; H Lichenstein; N Qureshi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Helicobacter pylori lipopolysaccharide can activate 70Z/3 cells via CD14.

Authors:  T Kirkland; S Viriyakosol; G I Perez-Perez; M J Blaser
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

7.  Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Authors:  Daniel P Rossignol; Kishor M Wasan; Eugene Choo; Edwin Yau; Nancy Wong; Jeffrey Rose; Jeffrey Moran; Melvyn Lynn
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist.

Authors:  S Kobayashi; T Kawata; A Kimura; K Miyamoto; K Katayama; I Yamatsu; D P Rossignol; W J Christ; Y Kishi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses.

Authors:  Martha Triantafilou; Klaus Brandenburg; Shoichi Kusumoto; Koichi Fukase; Alan Mackie; Ulrich Seydel; Kathy Triantafilou
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

10.  Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

Authors:  Kishor M Wasan; Verica Risovic; Olena Sivak; Stephen D Lee; Douglas X Mason; Gregory R Chiklis; Jim McShane; Melvyn Lynn; Nancy Wong; Daniel P Rossignol
Journal:  Pharm Res       Date:  2007-09-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.